Showing 1-10 of 25 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| A wireless oxygen generating immune protection device to support long term cell transplantation for the treatment of Type I Diabetes | Boston Children's Hospital | Robert Langer | Cures | 01-August-2025 to 31-July-2028 | $2.481.286,98 |
| Innovation Partnership | LabCentral | Luke Wallrich | Cures | 07-July-2025 to 31-May-2026 | $200.000,00 |
| Targeting RNLS for Type 1 Diabetes Therapy | Joslin Diabetes Center Inc. | Peng Yi | Cures | 01-June-2025 to 31-May-2028 | $1.349.997,00 |
| T1D Global Access Grand Strategy | Clinton Health Access Initiative (CHAI) | Nine Steensma | Mission | 01-August-2024 to 30-September-2025 | $1.179.001,50 |
| Expanding Access to T1D Care through the PEN-Plus Strategy | The Brigham and Women’s Hospital, Inc. | Gene Bukhman | Mission | 01-August-2024 to 31-July-2027 | $5.999.961,29 |
| Closing the T1D diagnosis gap in Ethiopia, Ghana and Nigeria | Clinton Health Access Initiative (CHAI) | Margaret Prust | Mission | 01-September-2023 to 31-August-2026 | $1.702.076,57 |
| Engineered Nanobodies to Visualize and Direct Antigen-Specific Tolerance in T1D | Boston Children's Hospital | Novalia Pishesha | Cures | 01-March-2025 to 28-February-2030 | $999.999,00 |
| Integration of Slow-Release A1AT-loaded Nanoparticles for Enhanced Cell Therapy in Type 1 Diabetes | Beth Israel Deaconess Medical Center Inc | Giuseppe Pettinato | Cures | 01-October-2024 to 30-September-2025 | $200.000,00 |
| In vivo interactions and trafficking of islet antigen-specific human effector T cells and Tregs | University of Massachusetts Medical School | Michael Brehm | Cures | 01-November-2024 to 31-October-2027 | $825.000,00 |
| New lipid biomarker to predict early risk for Type 1 diabetes | Beth Israel Deaconess Medical Center Inc | Barbara Kahn | Cures | 01-September-2024 to 31-August-2027 | $899.997,53 |